Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Santarus, Pharming Group submit Biologics License Application to FDA for RUCONEST

Santarus, Inc. and Pharming Group NV today announced the submission of a Biologics License Application to the U.S. Food and Drug Administration to obtain marketing approval for RUCONEST (recombinant human C1 esterase inhibitor) 50 U/kg, an investigational drug for the treatment of acute angioedema attacks in patients with hereditary angioedema.

17 Apr 2013

Researchers use atomic force microscopy technique to read information encoded in gut lining

A new technique based on atomic force microscopy was developed at the Institute of Food Research to help 'read' information encoded in the gut lining.

15 Apr 2013

Lipid Therapeutics to proceed with US LT-02 Phase III trial for mild-moderate ulcerative colitis

Lipid Therapeutics announces today that it has successfully filed its first US IND for its lead product LT-02 and is now in a position to proceed with a planned Phase III trial in the US in mild-moderate ulcerative colitis patients. The LT-02 IND was subject to the FDA's customary 30 day review period.

11 Apr 2013

FMT treatment improves symptoms in pediatric patients with active ulcerative colitis

A Spectrum Health clinical trial has found that fecal microbial transplantation (FMT) has resulted in the improvement or absence of symptoms in most pediatric patients with active ulcerative colitis.

7 Apr 2013

Ulcerative colitis and Crohn’s disease treatments: an interview with Dr Parikh, vice president, general medicine, Takeda

Ulcerative colitis (UC) and Crohn’s disease (CD) are both relapsing and remitting chronic diseases of bowel inflammation. By that I mean they flare and physicians try to get the flare under control and try to induce remission. However, despite a number of treatments available, they tend to relapse.

From Takeda 3 Apr 2013

Researchers identify link between immune response and blood clotting

Rice University researchers have found an unexpected link between a protein that triggers the formation of blood clots and other proteins that are essential for the body's immune system.

2 Apr 2013

LabCorp launches expanded IBD testing profile

Laboratory Corporation of America Holdings announced today the availability of an expanded testing menu to help clinicians diagnose, treat and monitor the course of Inflammatory Bowel Disease.

1 Apr 2013

Experts outline new agenda for inflammatory bowel disease research

Every five years, the Crohn's & Colitis Foundation of America gathers top researchers in inflammatory bowel disease to set the research agenda for the next five years.

25 Mar 2013

Investigational treatment for ulcerative colitis (UC) and Crohn’s disease (CD) has Marketing Authorisation Application submitted

Takeda Pharmaceutical Company Limited (“Takeda”) today announced that a Marketing Authorisation Application (MAA) has been submitted to The European Medicines Agency (EMA) for vedolizumab, an investigational, gut-selective humanized monoclonal antibody for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD), the two most common types of inflammatory bowel disease (IBD).

8 Mar 2013

University of Manchester leads systems medicine research network for inflammatory bowel disease

The University of Manchester is leading a €12 million systems medicine research network to identify better treatments for Inflammatory Bowel Disease like Crohn's Disease.

6 Mar 2013

SIRT1 gene may be involved in development of type 1 diabetes

A JDRF-funded study out of Switzerland has shown that a single gene called SIRT1 may be involved in the development of type 1 diabetes (T1D) and other autoimmune diseases. The study, "Identification of a SIRT1 Mutation in a Family with Type 1 Diabetes," was published today in Cell Metabolism and represents the first demonstration of a monogenetic defect leading to the onset of T1D.

6 Mar 2013

No increased risk for inflammatory bowel disease with isotretinoin

Researchers report no link between isotretinoin use for the treatment of acne and increased risk for inflammatory bowel disease in women of reproductive age.

1 Mar 2013

EpiCept fourth quarter revenue decreases to $0.1 million

EpiCept Corporation today announced operating and financial results for the fourth quarter and full year ended December 31, 2012, and provided an update on the Company's merger with Immune Pharmaceuticals, Ltd. (Immune).

28 Feb 2013

Scientists identify two populations of human cells that migrate to the intestine

Researchers at Wake Forest Baptist Medical Center and colleagues have identified a special population of adult stem cells in bone marrow that have the natural ability to migrate to the intestine and produce intestinal cells, suggesting their potential to restore healthy tissue in patients with inflammatory bowel disease (IBD).

28 Feb 2013

Avaxia initiates AVX-470 Phase 1b clinical study in ulcerative colitis

Avaxia Biologics, Inc., a clinical-stage biopharmaceutical company developing gut-targeted therapeutics, announced today that the first patient has been dosed in a Phase 1b clinical study of AVX-470, an oral anti-TNF antibody, for the treatment of ulcerative colitis.

25 Feb 2013

Immune Pharmaceuticals commences Phase II study with bertilimumab to treat ulcerative colitis

Immune Pharmaceuticals Ltd., a privately held Israeli company, and EpiCept Corporation announced today that Immune is initiating, following authorization from Israeli health authorities, a Phase II double-blind placebo controlled study with its lead drug, bertilimumab, in patients with moderate-to-severe ulcerative colitis.

21 Feb 2013

Santarus launches UCERIS for induction of remission in patients with ulcerative colitis

Santarus, Inc. announced today the U.S. commercial launch of UCERIS (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis.

14 Feb 2013

Research sheds light on how E. coli thrive in the intestine of people with IBD

Scientists have long puzzled over why "bad" bacteria such as E. coli can thrive in the guts of those with inflammatory bowel disease (IBD), causing serious diarrhea. Now UC Davis researchers have discovered the answer-one that may be the first step toward finding new and better treatments for IBD.

10 Feb 2013

DRCRF announces recipients of Nov. 2012 Damon Runyon Fellows

The Damon Runyon Cancer Research Foundation, a non-profit organization focused on supporting innovative early career researchers, named 15 new Damon Runyon Fellows at its fall Fellowship Award Committee review.

29 Jan 2013

Simple urine test picks up mesalamine non-adherence

A readily available urine test could identify ulcerative colitis patients who are non-adherent to their mesalamine therapy, research shows.

25 Jan 2013

Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Santarus, Pharming Group submit Biologics License Application to FDA for RUCONEST

Researchers use atomic force microscopy technique to read information encoded in gut lining

Lipid Therapeutics to proceed with US LT-02 Phase III trial for mild-moderate ulcerative colitis

FMT treatment improves symptoms in pediatric patients with active ulcerative colitis

Ulcerative colitis and Crohn’s disease treatments: an interview with Dr Parikh, vice president, general medicine, Takeda

Researchers identify link between immune response and blood clotting

LabCorp launches expanded IBD testing profile

Experts outline new agenda for inflammatory bowel disease research

Investigational treatment for ulcerative colitis (UC) and Crohn’s disease (CD) has Marketing Authorisation Application submitted

University of Manchester leads systems medicine research network for inflammatory bowel disease

SIRT1 gene may be involved in development of type 1 diabetes

No increased risk for inflammatory bowel disease with isotretinoin

EpiCept fourth quarter revenue decreases to $0.1 million

Scientists identify two populations of human cells that migrate to the intestine

Avaxia initiates AVX-470 Phase 1b clinical study in ulcerative colitis

Immune Pharmaceuticals commences Phase II study with bertilimumab to treat ulcerative colitis

Santarus launches UCERIS for induction of remission in patients with ulcerative colitis

Research sheds light on how E. coli thrive in the intestine of people with IBD

DRCRF announces recipients of Nov. 2012 Damon Runyon Fellows

Simple urine test picks up mesalamine non-adherence

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Newsletters you may be interested in